Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Precipitation Titration: Endpoint Detection Methods01:19

Precipitation Titration: Endpoint Detection Methods

5.9K
In argentometric precipitation titrations, endpoints can be detected visually by the Mohr, Volhard, and Fajans methods. In the Mohr method, adding a soluble chromate indicator gives an initial yellow color to the analyte solution. As the titrant is added, the first excess of silver ions forms a red silver chromate precipitate, marking the endpoint. The solution pH should be maintained at about 8 by adding solid CaCO3.
In the Volhard method, a standard excess of AgNO3 is first added to the...
5.9K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.4K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.4K
Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Data Validation01:03

Data Validation

6.4K
Data validation is an essential part of a comprehensive assessment. Validation is confirming or verifying and opening the door to gathering more assessment data as it clarifies vague or unclear data. The process of checking and verifying the collected information is called data validation. The primary purpose of data validation is to ensure data is as free from error, bias, and misinterpretation as possible.
Nursing assessment guides are generally based on holistic models rather than medical...
6.4K
Data Validation01:15

Data Validation

732
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Empirical Comparison of Win Ratio and Joint Frailty Models for Recurrent Event Endpoints With Applications in Oncology and Cardiology.

Statistics in medicine·2026
Same author

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival.

Statistics in medicine·2026
Same author

The DeepJoint Algorithm: An Innovative Approach for Studying the Longitudinal Evolution of Quantitative Mammographic Density and Its Association With Screen-Detected Breast Cancer Risk.

Biometrical journal. Biometrische Zeitschrift·2026
Same author

Permutation Tests Based on the Copula-Graphic Estimator and Their Use for Survival Tree Construction.

Statistics in medicine·2026
Same author

Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease-Free Survival.

Biometrical journal. Biometrische Zeitschrift·2025
Same author

Bayesian parametric estimation based on left-truncated competing risks data under bivariate Clayton copula models.

Journal of applied statistics·2024

Related Experiment Video

Updated: Jan 26, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K

One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with

Casimir Ledoux Sofeu1, Takeshi Emura2, Virginie Rondeau1

  • 1INSERM U1219 (Biostatistic), Université Bordeaux Segalen, Bordeaux, France.

Statistics in Medicine
|April 19, 2019
PubMed
Summary

We developed a new one-step method to validate surrogate endpoints using a joint frailty model. This approach improves treatment efficiency assessment by reliably evaluating individual and trial-level surrogacy.

Keywords:
cancers clinical trialsjoint frailty modelsmeta-analysisnumerical integrationone-step validation methodsurrogate endpoint

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
03:26

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

3.5K

Related Experiment Videos

Last Updated: Jan 26, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
03:26

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

3.5K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Cancer Research

Background:

  • Surrogate endpoints are crucial for assessing new treatment efficacy when direct clinical endpoints are delayed or infrequent.
  • Current validation methods for surrogate endpoints, often meta-analysis based, face limitations, particularly with the coefficient of determination () availability.
  • Existing two-step validation strategies can be constrained by data requirements and model estimation challenges.

Purpose of the Study:

  • To propose and evaluate a novel one-step validation approach for surrogate endpoints.
  • To introduce a joint frailty model incorporating individual- and trial-level random effects for enhanced validation.
  • To assess both individual- and trial-level surrogacy using updated measures of association.

Main Methods:

  • A one-step validation strategy using a joint frailty model with individual- and trial-level random effects was developed.
  • Parameter estimation employed a semiparametric penalized marginal log-likelihood method.
  • New definitions for Kendall's τ and the coefficient of determination were used to evaluate surrogacy.

Main Results:

  • Simulation studies demonstrated satisfactory performance of the proposed estimators.
  • The joint frailty model effectively estimated both individual- and trial-level surrogacy.
  • The model was successfully applied to individual patient data meta-analyses in gastric cancer.

Conclusions:

  • The proposed one-step joint frailty model offers a robust and flexible approach for surrogate endpoint validation.
  • This method addresses limitations of existing techniques, particularly when the coefficient of determination is unavailable.
  • The validated surrogate endpoint (disease-free survival for overall survival) aids in evaluating adjuvant therapies in gastric cancer.